etudiant
Different vaccine. Pfizer have described two candidate vaccines: BNT162b1 (your link) and BNT162b2. Because of the results that you link to, BNT162b2 (which had lower reactogenicity) was the candidate that was taken forward to the phase II/III trials that are now being reported. Article here:
https://www.nature.com/articles/s41586-020-2814-7